SCHEMBL22982098

SCHEMBL22982098

CCN1CCc2ccc(Cn3cc(C(=O)NCc4c(-n5cnc(C(F)(F)F)n5)ccc(OC)c4F)c(COC)n3)cc2C1

nearest known ligand 0.82

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ KLKB1 P03952 7/20 0.82
▸ F11 P03951 13/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29407265 1.00 KLKB1 (0.82) KLKB1F11
SCHEMBL29407012 0.98 KLKB1 (0.82) KLKB1F11
SCHEMBL29406741 0.93 F11 (0.91) KLKB1F11
SCHEMBL22993233 0.92 F11 (0.87) KLKB1F11
SCHEMBL29697500 0.91 KLKB1 (0.81) KLKB1F11
SCHEMBL29407029 0.90 KLKB1 (1.00) KLKB1F11
SCHEMBL22982045 0.90 KLKB1 (1.00) KLKB1F11
SCHEMBL22981129 0.90 F11 (0.82) KLKB1F11
SCHEMBL29697546 0.90 F11 (0.82) KLKB1F11
SCHEMBL29407053 0.89 KLKB1 (0.81) KLKB1F11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4010333-A1 PLASMA KALLIKREIN INHIBITORS Kalvista Pharmaceuticals Limited (GB) 2022-06-15 — — EP claimed
WO-2021028645-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO claimed
WO-2021028649-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO claimed
EP-4010333-A1 PLASMA KALLIKREIN INHIBITORS Kalvista Pharmaceuticals Limited (GB) 2022-06-15 — — EP disclosed
WO-2021028645-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO disclosed
WO-2021028649-A1 PLASMA KALLIKREIN INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2021-02-18 — — WO disclosed
Send feedback